Brief: Oxigene says Phase 2 study of CA4P met primary endpoint of improvement

Oncotelic Therapeutics

24/05/2016 11:30

May 24 (Reuters) - Oxigene Inc  OXGN.O : 
    * Oxigene announces results of Phase 2 study of CA4P in 
recurrent ovarian cancer published in journal of clinical 
oncology 
    * Study met primary endpoint of improvement in progression 
free survival 
    * Preliminary data show improvement in overall survival of 
2.6 months 
    * Preliminary median overall survival was longer for 
patients receiving CA4P combination than for control 
 
Source text for Eikon:  ID:nGNXMSRSLa  
Further company coverage:  OXGN.O  
 
 (Bengaluru Newsroom: +1-646-223-8780)